An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia

Plain-language summary

This study examines a retinal gene therapy (the rAAV2.REP1 vector) for choroideremia, an inherited eye disease. Men aged 18 and older diagnosed with choroideremia and active retinal degeneration were able to take part. The study was carried out in Phase 1/Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE1/PHASE2

Status

Completed

Sponsor

University of Alberta

Intervention

rAAV2.REP1 vector

Start date

4/1/2015

Estimated completion

5/16/2022

Countries

Canada

Related genes

Locations

• Edmonton, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* The research subject is willing and able to give informed consent for participation in the study.
* Male aged 18 years or above.
* Diagnosed with choroideremia (with genotyping or evidence of lack of the gene product with immunohistochemistry) and in good health.
* Active degeneration of the retina (the expectation of significant decline in visual function without any intervention over the subsequent 5 years) with OCT (optical coherent tomography) changes visible within the macula.
* Willingness to allow his general physician and ophthalmologist, if appropriate, to be notified of participation in the study.

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply.

* Female or child research subject (under the age of 18).
* Men unwilling to use barrier contraception methods, if relevant.
* Previous history of retinal surgery or ocular inflammatory disease (uveitis).
* Grossly asymmetrical retinal disease or other ocular morbidity which might confound adopting the fellow eye as a long-term comparator.
* Any other significant systemic disease or disorder which, in the opinion of the investigator, may either put the research subject at risk because of participation in the study, or may influence the result of the study, or the research subject's ability to participate in the study. This would include a contraindication to oral prednisolone, such as a history of gastric ulcer).
* Research subjects who have participated in another research study involving an investigational product within the past year.